Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug curb opioid addiction? a trial puts semaglutide to the test

NCT ID NCT06548490

Recruiting now Disease control Sponsor: Milton S. Hershey Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This phase 2 trial tests whether semaglutide, a GLP-1 drug used for diabetes and weight loss, can help adults with opioid use disorder avoid using illicit opioids. Participants already receiving buprenorphine or methadone treatment will take weekly semaglutide or a placebo for 12 weeks. The study tracks abstinence through urine tests and self-reports, aiming to see if semaglutide increases the likelihood of staying opioid-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide (Ozempic) given as a weekly injection
What this could lead to
If it works, semaglutide could become a new treatment option to help people with opioid use disorder reduce or stop using illicit opioids.
What could go wrong
This is a phase 2 trial with 200 participants, so results are still uncertain. Semaglutide can cause gastrointestinal side effects, and it is not yet known if it will meaningfully reduce opioid use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMICALLY-INDUCED DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavior, Addictive Chemically-Induced Disorders mental disorder Narcotic-Related Disorders opiate dependence opioid abuse psychiatric disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMICALLY-INDUCED DISORDERS MENTAL DISORDER NARCOTIC-RELATED DISORDERS OPIOID OPIOID ABUSE AND ADDICTION OPIOID USE DISORDER SUBSTANCE-RELATED DISORDERS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Pennsylvania Psychiatric Institute

    RECRUITING

    Harrisburg, Pennsylvania, 17110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

  • Stanley Street Treatment and Resources

    NOT_YET_RECRUITING

    Fall River, Massachusetts, 02720, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Maryland Baltimore

    COMPLETED

    Baltimore, Maryland, 21223, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.